Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma
Top Cited Papers
- 31 May 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 269 (6), 1154-1162
- https://doi.org/10.1097/SLA.0000000000002734
Abstract
Objectives: To establish an evidence-based cut-off to differentiate between early and late recurrence and to compare clinicopathologic risk factors between the two groups. Summary Background Data: A clear definition of "early recurrence'' after pancreatic ductal adenocarcinoma resection is currently lacking. Methods: Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma between 2000 and 2013 were included. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. A minimum P-value approach was used to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into early and late recurrence cohorts based on subsequent prognosis. Potential risk factors for early recurrence were assessed with logistic regression models. Results: Of 957 included patients, 204 (21.3%) were recurrence-free at last follow-up. The optimal length of recurrence-free survival to distinguish between early (n = 388, 51.5%) and late recurrence (n = 365, 48.5%) was 12 months (P < 0.001). Patients with early recurrence had 1-, and 2-year post-recurrence survival rates of 20 and 6% compared with 45 and 22% for the late recurrence group (both P < 0.001). Preoperative risk factors for early recurrence included a Charlson age-comorbidity index >= 4 (OR 1.65), tumor size > 3.0cm on computed tomography (OR 1.53) and CA 19-9 > 210 U/mL (OR 2.30). Postoperative risk factors consisted of poor tumor differentiation grade (OR 1.66), microscopic lymphovascular invasion (OR 1.70), a lymph node ratio > 0.2 (OR 2.49), and CA 19-9 > 37 U/mL (OR 3.38). Adjuvant chemotherapy (OR 0.28) and chemoradiotherapy (OR 0.29) were associated with a reduced likelihood of early recurrence. Conclusion: A recurrence-free interval of 12 months is the optimal threshold for differentiating between early and late recurrence, based on subsequent prognosis.Keywords
This publication has 42 references indexed in Scilit:
- Resection of isolated local and metastatic recurrence in periampullary adenocarcinomaHPB, 2014
- Recent progress in pancreatic cancerCA: A Cancer Journal for Clinicians, 2013
- CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic CancerInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trialsSurgery, 2011
- Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?Journal of Gastrointestinal Surgery, 2009
- Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinomaCancer, 2009
- Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704Journal of Clinical Oncology, 2008
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic HeadJournal of Clinical Oncology, 2008
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987